Key Points
- Insider sale: Joana Goncalves sold 7,000 shares on Dec. 19 at an average price of $30.61 for roughly $214,270, leaving her with 1,518 shares — an 82.18% reduction in her position.
- Stock move and valuation: Shares jumped about 13.1%, opening at $31.84; the company has a market cap of $1.54 billion and a 52‑week range of $5.49 to $32.28.
- Investor and analyst backdrop: Institutional investors own 56.44% of the stock and analysts have a consensus “Moderate Buy” rating with a $48.88 average target, while individual targets range roughly from $40 to $75.
Oruka Therapeutics, Inc. (NASDAQ:ORKA - Get Free Report) insider Joana Goncalves sold 7,000 shares of the company's stock in a transaction on Friday, December 19th. The stock was sold at an average price of $30.61, for a total value of $214,270.00. Following the sale, the insider owned 1,518 shares of the company's stock, valued at $46,465.98. This trade represents a 82.18% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this hyperlink.
Oruka Therapeutics Trading Up 13.1%
Shares of NASDAQ:ORKA opened at $31.84 on Friday. The stock has a market cap of $1.54 billion, a PE ratio of -16.76 and a beta of -0.41. The stock's fifty day simple moving average is $28.46 and its two-hundred day simple moving average is $19.52. Oruka Therapeutics, Inc. has a 1-year low of $5.49 and a 1-year high of $32.28.
Oruka Therapeutics (NASDAQ:ORKA - Get Free Report) last posted its earnings results on Wednesday, November 12th. The company reported ($0.55) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.56) by $0.01. On average, sell-side analysts forecast that Oruka Therapeutics, Inc. will post -3.41 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Oruka Therapeutics
Institutional investors have recently bought and sold shares of the company. Fairmount Funds Management LLC grew its holdings in Oruka Therapeutics by 9.9% during the third quarter. Fairmount Funds Management LLC now owns 3,705,262 shares of the company's stock valued at $71,252,000 after purchasing an additional 333,340 shares during the period. Viking Global Investors LP bought a new stake in shares of Oruka Therapeutics in the third quarter valued at $51,280,000. Deep Track Capital LP lifted its position in shares of Oruka Therapeutics by 38.4% during the 3rd quarter. Deep Track Capital LP now owns 2,654,781 shares of the company's stock valued at $51,051,000 after buying an additional 735,983 shares during the last quarter. Commodore Capital LP grew its stake in shares of Oruka Therapeutics by 23.5% during the 3rd quarter. Commodore Capital LP now owns 1,753,054 shares of the company's stock worth $33,711,000 after acquiring an additional 333,340 shares during the period. Finally, Braidwell LP grew its stake in shares of Oruka Therapeutics by 37.0% during the 1st quarter. Braidwell LP now owns 1,572,426 shares of the company's stock worth $16,133,000 after acquiring an additional 424,750 shares during the period. Hedge funds and other institutional investors own 56.44% of the company's stock.
Analyst Upgrades and Downgrades
Several equities analysts have commented on the stock. HC Wainwright dropped their target price on shares of Oruka Therapeutics from $45.00 to $40.00 and set a "buy" rating on the stock in a research report on Monday, October 27th. BTIG Research increased their price target on Oruka Therapeutics from $56.00 to $63.00 and gave the company a "buy" rating in a research report on Thursday, November 13th. Piper Sandler started coverage on Oruka Therapeutics in a research report on Thursday. They issued an "overweight" rating and a $75.00 price objective on the stock. Weiss Ratings restated a "sell (d-)" rating on shares of Oruka Therapeutics in a research note on Wednesday, October 8th. Finally, Wall Street Zen lowered Oruka Therapeutics from a "hold" rating to a "sell" rating in a research report on Sunday, November 16th. One investment analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Oruka Therapeutics presently has an average rating of "Moderate Buy" and a consensus price target of $48.88.
View Our Latest Stock Analysis on ORKA
Oruka Therapeutics Company Profile
(
Get Free Report)
Oruka Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of novel peptide‐based therapies for oncology. The company's proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell‐permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”
The company's lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
